SCHEMBL30348762

SCHEMBL30348762

Cc1nc2ccc(-c3c[nH]c4nc(Nc5ccnc(N6CCN(C)CC6)c5)ncc34)nc2n1C(C)C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK2 P49760 1/20 0.61
CLK3 P49761 1/20 0.61
DYRK1A Q13627 1/20 0.61
CDK2 P24941 4/20 0.44
FLT3 P36888 2/20 0.44
CDK1 P06493 1/20 0.44
CCNB1 P14635 1/20 0.44
CCNE1 P24864 1/20 0.44
CDK7 P50613 1/20 0.44
CCNH P51946 1/20 0.44
MNAT1 P51948 1/20 0.44
EGFR P00533 11/20 0.41
KDR P35968 5/20 0.41
CDK6 Q00534 1/20 0.40
CCNT1 O60563 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK9 P50750 1/20 0.39
IGF1R P08069 2/20 0.38
DYRK1B Q9Y463 2/20 0.38
RET P07949 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25156971 1.00 CLK2 (0.61) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL25156872 0.89 CLK2 (0.47) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL30348331 0.89 CLK2 (0.47) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL25437345 0.88 FLT3 (0.56) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL30347500 0.88 FLT3 (0.56) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL25208280 0.87 DYRK1A (0.58) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL30346544 0.87 DYRK1A (0.58) CLK2CLK3DYRK1ACDK2FLT3
SCHEMBL30348765 0.83 DYRK1A (0.40) CLK2CLK3DYRK1ACDK2CDK1
SCHEMBL25156920 0.83 DYRK1A (0.40) CLK2CLK3DYRK1ACDK2CDK1
SCHEMBL31568796 0.81 DYRK1A (0.39) CLK2CLK3DYRK1ACDK2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-04-24 US claimed
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 EP claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 CLK2 466/4885CLK3 1147/4885DYRK1A 1/4885
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 CLK2 466/4885CLK3 1147/4885DYRK1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.